Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Manesh R Patel

Showing results (491-500 of 596) with videos related to

Pageof 60
Sort By:
American Heart Journal|December 9, 2020
Individual Patient Data from the Pivotal Randomized Controlled Trials of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation (COMBINE AF): Design and Rationale: From the COMBINE AF (A Collaboration between Multiple institutions to Better Investigate Non-vitamin K antagonist oral anticoagulant use in Atrial Fibrillation) InvestigatorsAnthony P Carnicelli, Hwanhee Hong, Robert P Giugliano, et al.
Journal of the American College of Cardiology|September 4, 2024
Heart Failure Risk Assessment Using Biomarkers in Patients With Atrial Fibrillation: Analysis From COMBINE-AFPaul M Haller, Petr Jarolim, Michael G Palazzolo, et al.
Journal of the American College of Cardiology|February 9, 2013
Outcomes of discontinuing rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: analysis from the ROCKET AF trial (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation)Manesh R Patel, Anne S Hellkamp, Yuliya Lokhnygina, et al.
Journal of Thrombosis and Thrombolysis|May 24, 2013
EPC mobilization after erythropoietin treatment in acute ST-elevation myocardial infarction: the REVEAL EPC substudyThomas J Povsic, Samer S Najjar, Kristi Prather, et al.
JACC. Cardiovascular Interventions|June 9, 2022
Clinical Outcomes in Patients With ST-Segment Elevation MI and No Standard Modifiable Cardiovascular Risk FactorsGemma A Figtree, Bjorn Redfors, Rebecca Kozor, et al.
Stroke|April 19, 2014
Intracranial hemorrhage among patients with atrial fibrillation anticoagulated with warfarin or rivaroxaban: the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillationGraeme J Hankey, Susanna R Stevens, Jonathan P Piccini, et al.
Journal of Cardiovascular Computed Tomography|January 21, 2024
Coronary computed tomography angiography derived fractional flow reserve and risk of recurrent angina: A 3-year follow-up studyKristian Tækker Madsen, Bjarne Linde Nørgaard, Kristian Altern Øvrehus, et al.
JACC. Advances|June 29, 2026
Clinical Patterns and Appropriateness of Apixaban Dosing in Patients With Atrial FibrillationPishoy Gouda, Josephine Harrington, Kelly Arps, et al.
Journal of the American Heart Association|March 10, 2016
Cause of Death and Predictors of All-Cause Mortality in Anticoagulated Patients With Nonvalvular Atrial Fibrillation: Data From ROCKET AFSean D Pokorney, Jonathan P Piccini, Susanna R Stevens, et al.
Journal of Thrombosis and Haemostasis : JTH|February 16, 2022
Prevention of arterial and venous thrombotic events in symptomatic peripheral arterial disease patients after lower extremity revascularization in the VOYAGER PAD trial: Dual anticoagulant/antiplatelet regimen vs antiplatelet therapy aloneScott D Berkowitz, Rupert M Bauersachs, Michael Szarek, et al.
Pageof 60

Showing results (491-500 of 596) with videos related to

Sort By:
Pageof 60
American Heart Journal|December 9, 2020
Individual Patient Data from the Pivotal Randomized Controlled Trials of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation (COMBINE AF): Design and Rationale: From the COMBINE AF (A Collaboration between Multiple institutions to Better Investigate Non-vitamin K antagonist oral anticoagulant use in Atrial Fibrillation) InvestigatorsAnthony P Carnicelli, Hwanhee Hong, Robert P Giugliano, et al.
Journal of the American College of Cardiology|September 4, 2024
Heart Failure Risk Assessment Using Biomarkers in Patients With Atrial Fibrillation: Analysis From COMBINE-AFPaul M Haller, Petr Jarolim, Michael G Palazzolo, et al.
Journal of the American College of Cardiology|February 9, 2013
Outcomes of discontinuing rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: analysis from the ROCKET AF trial (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation)Manesh R Patel, Anne S Hellkamp, Yuliya Lokhnygina, et al.
Journal of Thrombosis and Thrombolysis|May 24, 2013
EPC mobilization after erythropoietin treatment in acute ST-elevation myocardial infarction: the REVEAL EPC substudyThomas J Povsic, Samer S Najjar, Kristi Prather, et al.
JACC. Cardiovascular Interventions|June 9, 2022
Clinical Outcomes in Patients With ST-Segment Elevation MI and No Standard Modifiable Cardiovascular Risk FactorsGemma A Figtree, Bjorn Redfors, Rebecca Kozor, et al.
Stroke|April 19, 2014
Intracranial hemorrhage among patients with atrial fibrillation anticoagulated with warfarin or rivaroxaban: the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillationGraeme J Hankey, Susanna R Stevens, Jonathan P Piccini, et al.
Journal of Cardiovascular Computed Tomography|January 21, 2024
Coronary computed tomography angiography derived fractional flow reserve and risk of recurrent angina: A 3-year follow-up studyKristian Tækker Madsen, Bjarne Linde Nørgaard, Kristian Altern Øvrehus, et al.
JACC. Advances|June 29, 2026
Clinical Patterns and Appropriateness of Apixaban Dosing in Patients With Atrial FibrillationPishoy Gouda, Josephine Harrington, Kelly Arps, et al.
Journal of the American Heart Association|March 10, 2016
Cause of Death and Predictors of All-Cause Mortality in Anticoagulated Patients With Nonvalvular Atrial Fibrillation: Data From ROCKET AFSean D Pokorney, Jonathan P Piccini, Susanna R Stevens, et al.
Journal of Thrombosis and Haemostasis : JTH|February 16, 2022
Prevention of arterial and venous thrombotic events in symptomatic peripheral arterial disease patients after lower extremity revascularization in the VOYAGER PAD trial: Dual anticoagulant/antiplatelet regimen vs antiplatelet therapy aloneScott D Berkowitz, Rupert M Bauersachs, Michael Szarek, et al.
Pageof 60